Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYNAPSE-SMA
NCT05794139Phase 2Completed
- Sponsor
- NMD Pharma
- Start
- Sep 2023
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of ignaseclant in spinal muscular atrophy (SMA) (2 cohorts), sponsored by NMD Pharma. Primary endpoint: 6 Minute Walk Test total distance at 21 days. Started Sep 2023; status: completed.
02
Drugs
ignaseclant
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT05794139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05794139.